TSX VENTURE EXCHANGE - NEX · NGEN
+2.41% · +$0.0400 · Vol 597.1K
After hours · updated 16:45:04 ET
NervGen Pharma Corp

NervGen Pharma Corp

Pharmaceuticals
$1.70
Card
Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factorsMethodology
NGEN
NervGen Pharma Corp
Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET
AVOID

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

29/ 100
Veridion Score
AVOID · HIGH confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Score not reportedVeridion does not publish a score-history trend for NGEN until the ticker has a real scored snapshot. No trend is implied for this page.Review methodology
AI Analysis
Sovereign

Why is NGEN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading NGEN catalysts
About NervGen Pharma Corp
Pharmaceuticals
Listed since
2019
Employees
9
Country
CA

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.66
Day high
$1.75
Day low
$1.64
Previous close
$1.66
52W high
$5.97
-71.52% from high
52W low
$1.59
3% of range
Market cap
$176.6M
Beta
1.47
Shares out
106.4M
Volume
597.1K
0.86× rel vol
Avg volume
697.6K
VWAP
$1.69
Price history computed in-house
1W
+6.92%
1M
-19.43%
3M
-55.84%
SMA 50 $1.87 · below
SMA 200 Not reported · Not reported
52W position 3%

NGEN overview

Veridion Score
Not reported
6 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around NGEN.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading NGEN Form 4 filings
Public disclosures

Congress activity in NGEN

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for NGEN in the cached public ledger.

Federal contracts

NGEN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NGEN in this window.
Lobbying spend

NGEN lobbying filings, year to date.

Registered lobbying filings matched to NervGen Pharma Corp.

$100.0K
Refresh interval: 12hSource: LDA disclosure filings
Veterans Defense Health Issues
Filing
$50.0K
NERVGEN PHARMA CORP.

CORNERSTONE GOVERNMENT AFFAIRS, INC.

Jul 10, 2026
Filing
$50.0K
NERVGEN PHARMA CORP.

CORNERSTONE GOVERNMENT AFFAIRS, INC.

Apr 8, 2026
Loading news for NGEN
Analyst ratings
Sovereign unlock shows live analyst consensus for NGEN.
Options
Sovereign unlock shows live options positioning for NGEN.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.